Objective: To study the effects of long-term growth hormone (GH) treatment on left ventricular (LV) dimensions in children with Noonan’s syndrome (NS). Methods: Echocardiographic measurements of LV dimensions were performed before and during GH treatment in 27 participants (21 boys, 6 girls) in a partly controlled 3-year trial of high-dose GH treatment (0.15 IU/kg/day). Nineteen children had a congenital heart defect, 1 of them had hypertrophic obstructive cardiomyopathy. In the first 3 years, the children were assigned to 1 of 2 groups: group A with discontinuation of GH treatment in the 3rd year, or group B without GH treatment in the 1st year. After the 3rd year, 12 of the 27 children were followed up for 2 additional years to evaluate the long-term effects of GH treatment on the heart. Results: At baseline, LV internal diameters were smaller, while posterior wall thickness were thicker than normal. Over the 1st year, changes in LV dimensions were comparable between the 2 groups. No significant differences were found in LV dimensions between the situation at baseline and after 4 years of GH treatment. Conclusion: Long-term high-dose GH treatment does not have clinically significant adverse effects on LV dimensions in children with NS.

Noonan JA: Hypertelorism with Turner phenotype: A new syndrome with associated congenital heart disease. Am J Dis Child 1968;116:373–380.
Allanson JE: Noonan syndrome. J Med Genet 1987;24:9–13.
Sharland M, Burch M, McKenna WM, Patton MA: A clinical study of Noonan syndrome. Arch Dis Child 1992;67:178–183.
Ranke MB, Heidemann P, Knupfer C, Enders H, Schmaltz AA, Bierich JR: Noonan syndrome: Growth and clinical manifestations in 144 cases. Eur J Pediatr 1988;148:220–227.
Municchi G, Pasquino AM, Pucarelli I, Cianfarani S, Passeri F: Growth hormone treatment in Noonan syndrome: Report of four cases who reached final height. Horm Res 1995;44:164–167.
Ahmed ML, Foot AB, Edge JA, Lamkin VA, Savage MO, Dunger DB: Noonan’s syndrome: Abnormalities of the growth hormone/IGF-I axis and the response to treatment with human biosynthetic growth hormone. Acta Pediatr Scand 1991;80:446–450.
Thomas BC, Stanhope R: Long-term treatment with growth hormone in Noonan’s syndrome. Acta Pediatr 1993;82:853–855.
De Schepper J, Otten BJ, Francois I, Bourguignon JP, Craen M, van der Burgt I, Massa GG: Growth hormone therapy in pre-pubertal children with Noonan syndrome: First year growth response and comparison with Turner syndrome. Acta Paediatr 1997;86:943–946.
Romano AA, Blethen SL, Dana K, Noto RA: Growth hormone treatment in Noonan syndrome: The National Cooperative Growth Study experience. J Pediatr 1996;128:S18–S21.
Otten BJ, Noordam C: Short stature in Noonan syndrome: Demography and response to growth hormone treatment in KIGS; in Ranke MB, Wilton P (eds): Growth Hormone Therapy in KIGS –10 Years’ Experience. Heidelberg, Barth, 1999, pp 269–280.
Burch M, Sharland M, Shinebourne E, Smith G, Patton M, McKenna W: Cardiologic abnormalities in Noonan syndrome: Phenotypic diagnosis and echocardiographic assessment of 118 patients. J Am Coll Cardiol 1993;22:1189–1192.
Marino B, Digilio MC, Toscano A, Giannotti A, Dallapiccola B: Congenital heart diseases in children with Noonan syndrome: An expanded cardiac spectrum with high prevalence of atrioventricular canal. J Pediatr 1999;135:703–706.
Sacca L, Cittadini A, Fazio S: Growth hormone and the heart. Endocr Rev 1994;15:555–573.
Osterziel KJ, Strohm O, Schuler J, Friedrich M, Hanlein D, Willenbrock R, Anker SD, Poole Wilson PA, Ranke MB, Dietz R: Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure du to dilated cardiomyopathy. Lancet 1998;351:1233–1237.
Cotterill AM, McKenna WJ, Brady AF, Sharland M, Elsawi M, Yamada M, Camacho Hubner C, Kelnar CJ, Dunger DB, Patton MA, Savage MO: The short-term effects of growth hormone therapy on height velocity and cardiac ventricular wall thickness in children with Noonan’s syndrome. J Clin Endocrinol Metab 1996;81:2291–2297.
van der Burgt I, Berends E, Lommen E, van Beersum S, Hamel B, Mariman E: Clinical and molecular studies in a large Dutch family with Noonan syndrome. Am J Genet 1994;53:187–191.
Sobotka-Plojhar MA: Anthracycline cardiotoxicity in children an echocardiographic study; thesis VU University, Amsterdam, 1991, pp 97–100.
Kiraly P; Kapusta L, van Lier H, Otten Hofman A, Daniels O: Natural history of congenital aortic valvar stenosis: An echo and Doppler cardiographic study. Cardiol Young 1997;7:188–193.
Fredriks AM, van Buuren S, Burgmeyer RJF, Meulmeester JF, Beuker RJ, Brugman E, Roede MJ, Verloove-Vanhorick SP, Wit JM: Continuing positive secular growth change in the Netherlands 1955–1997. Pediatr Res 2000;47:316–323.
Lampit M, Lorber A, Vilkas DL, Nave T, Hochberg Z: GH dependence and GH withdrawal syndrome in GH treatment on short normal children: Evidence from growth and cardiac output. Eur J Endocrinol 1998;138:401–407.
Barton JS, Cullen S, Hindmarsh PC, Brook CG, Preece MA: Growth hormone treatment in idiopathic short stature: A preliminary analysis of cardiovascular effects. Acta Paediatr Suppl 1992;383:35–38.
Daubeney PE, McCaughey ES, Chase C, Walker JM, Slavik Z, Betts PR, Webber SA: Cardiac effects of growth hormone in short normal children: Results after four years of treatment. Arch Dis Child 1995;72:337–339.
Crepaz R, Pitscheider W, Radetti G, Paganini C, Gentili L, Morini G, Braito E, Mengarda G: Cardiovascular effects of high-dose growth hormone treatment in growth hormone-deficient children. Pediatr Cardiol 1995;16:223–227.
Bengtsson BA, Brummer RJ, Eden S, Bosaeus I, Lindstedt G: Body composition in acromegaly: The effect of treatment. Clin Endocrinol (Oxf) 1989;31:481–490.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.